$TALS News

Last published 3y ago

3y agoTALSTalaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioGlobeNewswireCombined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris")
3y agoTALSTalaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline BioGlobeNewswireSpecial dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris
3y agoTALSNew York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris TherapeuticsGlobeNewswireNEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and
3y agoDEN INPX RETA TALSMoore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law FirmGlobeNewswireNEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoAGLE MRTX ONCY POAI+1Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New DrugsPR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 22, 2023 /PRNewswire/ -- Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and
3y agoTALSTalaris Therapeutics and Tourmaline Bio Announce Merger AgreementGlobeNewswireMerger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline's anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD)
3y agoTALSTalaris Therapeutics Announces Leadership TransitionGlobeNewswireBOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of
3y agoTALSTalaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring PlanGlobeNewswireBOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced that it has completed a review of its business and program prospects. Based on this review,
3y agoTALSTalaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewswireBOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of
4y agoTALSTalaris Therapeutics Announces Third Quarter Financial Results and Corporate UpdateGlobeNewswireEnrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting Strong cash
4y agoTALSTalaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune ToleranceGlobeNewswireBOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of
4y agoTALSTalaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical TrialGlobeNewswireBOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of
4y agoTALSTalaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual MeetingGlobeNewswireBOSTON and LOUISVILLE, Ky., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of
4y agoTALSTalaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the MesaGlobeNewswireBOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
4y agoTALSTalaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual EventGlobeNewswireBOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
4y agoTALSTalaris Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswireBOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
4y agoTALSTalaris Therapeutics Announces Second Quarter Financial Results and Corporate UpdateGlobeNewswireAll FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued
4y agoTALSTalaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical UpdateGlobeNewswireAll three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff da
4y agoTALSTalaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022GlobeNewswireReal-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic complications than patients on immunosuppression after 5 years In long-term
4y agoTALSTalaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 StudyGlobeNewswireBOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
4y agoTALSTalaris Therapeutics to Present at the Jefferies Healthcare ConferenceGlobeNewswireBOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation a
4y agoTALSTalaris Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireBOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation a
4y agoTALSTalaris Therapeutics Announces Changes to Board of DirectorsGlobeNewswireBOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation a
4y agoTALSTalaris Therapeutics Announces First Quarter Financial Results and Corporate UpdateGlobeNewswireMultiple presentations pending at upcoming American Transplant Congress (ATC), as well as concurrent update on ongoing Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients Presented data on COVID-19 outcomes among kidne
4y agoTALSTalaris Therapeutics Announces Upcoming Presentations at American Transplant CongressGlobeNewswireData to be presented include real-world evidence analysis of health outcomes among Phase 2 patients compared to matched controls Updated data on Phase 2 study follow-up, COVID-19 patient outcomes also planned for ATC BOSTON and LOUISVILLE, Ky., Ma
4y agoTALSTalaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001GlobeNewswireLow rate of COVID-19 infection observed in vaccinated, durably chimeric patients off immunosuppression No evidence of acute kidney injury or impaired renal function in FCR001-treated patients with COVID-19 infection No patients lost chimerism as
4y agoTALSTalaris Therapeutics to Participate at Two Upcoming Investor ConferencesGlobeNewswireBOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
4y agoTALSTalaris Therapeutics Announces Fourth Quarter and Year-End Financial ResultsGlobeNewswirePhase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients continues; additional data update expected mid-year 2022 Two Phase 2 (FREEDOM-2 and FREEDOM-3) clinical trials of FCR001 initiated in delayed tolerance and scler
4y agoTALSTalaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireBOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
4y agoTALSTalaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
4y agoTALSTalaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual ConferenceGlobeNewswireBOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
4y agoTALS NBITalaris Therapeutics Announces Addition to the Nasdaq Biotechnology IndexGlobeNewswireBOSTON and LOUISVILLE, Ky., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
4y agoTALSTalaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney TransplantGlobeNewswireBOSTON and LOUISVILLE, Ky., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (NASDAQ:TALS), a late-clinical stage cell therapy company, today presented a new analysis of HLA mismatching between donors and recipients participating in the Co
4y agoTALSTalaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of SclerodermaGlobeNewswireBOSTON and LOUISVILLE, Ky., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
5y agoTALSTalaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireProvided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients Initiated Phase 2 (FREEDOM-2) clinical trial for FCR001 in delayed tolerance induction patients BOSTON and LOU
5y agoTALSTalaris Therapeutics to Participate at Three Upcoming Virtual Investor ConferencesGlobeNewswireBOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation,
5y agoTALSTalaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance InductionGlobeNewswireBOSTON, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe aut
5y agoTALSTalaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology MeetingGlobeNewswireCompany will share first clinical update on Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients Poster with additional data from Phase 2 study follow-up to be presented at ASN Talaris to host investor conference call on Novembe
5y agoTALSTalaris Therapeutics to Participate at Two Upcoming Virtual Investor ConferencesGlobeNewswireBOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
5y agoTALSTalaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireBOSTON and LOUISVILLE, Ky., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation,
5y agoTALSTalaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireBOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation,
5y agoTALSTalaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant CongressGlobeNewswireBOSTON and LOUISVILLE, Ky., June 03, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation,
5y agoTALSTalaris Therapeutics Announces Closing of Initial Public OfferingGlobeNewswireBOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation,
5y agoTALSTalaris Therapeutics Announces Pricing of Initial Public OfferingGlobeNewswireBOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe